In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not reduce recurrent stroke vs aspirin in the ARCADIA trial.
Despite surgical advances, adding extracranial-intracranial bypass to medical therapy does not reduce stroke or death in symptomatic occlusion of the internal carotid or middle cerebral artery.
National Health Insurance Service Ilsan Hospital Researcher Provides New Insights into Heart Attack (Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction): Heart Disorders and Diseases - Heart Attack - Insurance News insurancenewsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insurancenewsnet.com Daily Mail and Mail on Sunday newspapers.
Clinicians shouldn t expect apixaban to offer benefit over aspirin in patients with embolic stroke of undetermined source simply because they have atrial cardiopathy, ARCADIA investigators conclude.